Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients

Pancreas. 2008 Jul;37(1):94-100. doi: 10.1097/MPA.0b013e31816907ab.


Objective: Octreotide is used to treat patients with neuroendocrine tumors. Previous reports show that octreotide long-acting repeatable (LAR) dose and patient body weight affect nadir plasma octreotide levels (approximately 1250, 2500, 5000, and 11,000 pg/mL for LAR doses of 10, 20, 30 and 60 mg/mo). However, plasma octreotide levels have decreased over time in patients receiving these doses of LAR.

Methods: From November 2004 until July 2007, trough plasma octreotide levels were determined in 86 patients on long-term octreotide LAR therapy at doses of 30, 60, and 120 mg/mo. Changes in plasma drug levels were analyzed over time using random effects models.

Results: Current plasma octreotide levels for octreotide LAR doses of 30, 60, and 120 mg/mo are approximately 2200, 5200, and 6500 pg/mL, respectively, representing a decrease of approximately 50% to 70% compared with previously reported plasma octreotide levels. The decreases in octreotide levels over time with the 30- and 60-mg/mo LAR doses are highly statistically significant (P = 0.0067, 0.0149, respectively).

Conclusions: Current plasma octreotide values are significantly lower than previously reported for 30-, 60-, and 120-mg/mo LAR doses. Serial plasma octreotide value measurements should be used to determine if increasing symptoms or tumor growth are associated with suboptimal octreotide levels.

Publication types

  • Multicenter Study

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage*
  • Antineoplastic Agents, Hormonal / blood*
  • Carcinoid Tumor / drug therapy*
  • Carcinoid Tumor / metabolism
  • Delayed-Action Preparations
  • Drug Monitoring*
  • Humans
  • Injections, Intramuscular
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / metabolism
  • Octreotide / administration & dosage*
  • Octreotide / blood*
  • Prospective Studies
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome
  • United States


  • Antineoplastic Agents, Hormonal
  • Delayed-Action Preparations
  • Octreotide